Stuart Essig - 01 Jun 2026 Form 4 Insider Report for INTEGRA LIFESCIENCES HOLDINGS CORP (IART)

Reporting relationship: President and CEO, Director
Issuer ticker: IART
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 16:54:58 UTC
Prior SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Hutchinson; Attorney-in-Fact for Stuart Essig

Key filing fact

Stuart Essig filed Form 4 for INTEGRA LIFESCIENCES HOLDINGS CORP (IART) on 03 Jun 2026.

Key facts

This page summarizes Stuart Essig's Form 4 filing for INTEGRA LIFESCIENCES HOLDINGS CORP (IART).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Jun 2026, 16:54.

Change

Previous filing in this sequence was filed on 21 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001187574 Primary reporting owner

ESSIG STUART

Relationship: President and CEO, Director
Address: 1100 CAMPUS ROAD, PRINCETON
Signature: /s/ Michael Hutchinson; Attorney-in-Fact for Stuart Essig
Signature date: 03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IART transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +705,468
Change %
Price: $0.000000^*
Shares after: 705,468
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 705,468
Exercise price: $15.67
Footnotes: F1

IART transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +365,297
Change %
Price: $0.000000^*
Shares after: 365,297
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 365,297
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

Footnote F2

Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.